5 results match your criteria: "Department of Microbiology at the Icahn School of Medicine at Mount Sinai[Affiliation]"

Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina.

Lancet Reg Health Am

February 2022

Instituto de Investigación en Medicina Molecular y Celular Aplicada IMMCA (UNT-CONICET-SIPROSA). Tucumán, Argentina.

Background: Gam-COVID-Vac (SPUTNIK V) has been granted emergency use authorization in 70 nations and has been administered to millions worldwide. However, there are very few peer-reviewed studies describing its effects. Independent reports regarding safety and effectiveness could accelerate the final approval by the WHO.

View Article and Find Full Text PDF

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected at least 180 million people since its identification as the cause of the current COVID-19 pandemic. The rapid pace of vaccine development has resulted in multiple vaccines already in use worldwide. The contemporaneous emergence of SARS-CoV-2 'variants of concern' (VOC) across diverse geographic locales underscores the need to monitor the efficacy of vaccines being administered globally.

View Article and Find Full Text PDF

The novel pandemic betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected at least 120 million people since its identification as the cause of a December 2019 viral pneumonia outbreak in Wuhan, China1,2. Despite the unprecedented pace of vaccine development, with six vaccines already in use worldwide, the emergence of SARS-CoV-2 'variants of concern' (VOC) across diverse geographic locales have prompted re-evaluation of strategies to achieve universal vaccination3. All three officially designated VOC carry Spike (S) polymorphisms thought to enable escape from neutralizing antibodies elicited during initial waves of the pandemic4-8.

View Article and Find Full Text PDF
Article Synopsis
  • The pandemic caused by SARS-CoV-2 has infected over 120 million people globally since its emergence in late 2019, leading to rapid vaccine development with six vaccines available.
  • The rise of 'variants of concern' for the virus—specifically B.1.1.7 and B.1.351—raises doubts about the effectiveness of current vaccines due to mutations that help the virus evade neutralizing antibodies.
  • Research shows that only one serum sample from vaccinated individuals effectively neutralized the B.1.351 variant, suggesting newer vaccine formulations may be necessary to address these emerging variants effectively.
View Article and Find Full Text PDF

The antigenic and genomic stability of paramyxoviruses remains a mystery. Here, we evaluate the genetic plasticity of Sendai virus (SeV) and mumps virus (MuV), sialic acid-using paramyxoviruses that infect mammals from two Paramyxoviridae subfamilies (Orthoparamyxovirinae and Rubulavirinae). We performed saturating whole-genome transposon insertional mutagenesis, and identified important commonalities: disordered regions in the N and P genes near the 3' genomic end were more tolerant to insertional disruptions; but the envelope glycoproteins were not, highlighting structural constraints that contribute to the restricted antigenic drift in paramyxoviruses.

View Article and Find Full Text PDF